[Risk-factor analysis of poor graft function after allogeneic hematopoietic stem cell transplantation for severe aplastic anemia].

Objective: To investigate the risk factors of poor graft function (PGF) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for severe aplastic anemia (SAA) . Methods: Clinical data from 111 SAA patients who received allo-HSCT were analyzed retrospectively. Factors including age, gender, interval to transplantation, the level of serum ferritin before transplantation were analyzed by Cox multivariate regression analysis. Results: Among the 111 patients who underwent allo-HSCT, 16 developed PGF (14.4%) . Multivariate analysis showed donor type (HR=2.656, 95%CI 1.204-5.858, P= 0.016) and the level of serum ferritin before tansplantation (HR=3.170, 95%CI 1.400-7.180, P=0.006) were significant risk factors for PGF. Conclusion: Unrelated donor transplantation and the high level of serum ferritin before transplantation are risk factors for PGF.

[1]  R. Storb,et al.  Hematopoietic stem cell transplantation for acquired aplastic anemia , 2016, Current opinion in hematology.

[2]  A. Bacigalupo,et al.  Bone marrow transplantation versus immunosuppressive therapy in patients with acquired severe aplastic anemia , 2016, International Journal of Hematology.

[3]  N. Kröger,et al.  Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis , 2016, Bone Marrow Transplantation.

[4]  G. Goteri,et al.  Reversal of poor graft function with iron-chelating therapy after allogeneic transplantation for severe aplastic anemia , 2016, Leukemia and Lymphoma.

[5]  Yu-Hong Chen,et al.  The incidence, risk factors, and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantation , 2015, Annals of Hematology.

[6]  H. Sengeløv,et al.  Treatment of poor graft function after allogeneic hematopoietic cell transplantation with a booster of CD34-selected cells infused without conditioning , 2014, Bone Marrow Transplantation.

[7]  Yonghua Li,et al.  Risk-Factor Analysis of Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation , 2014, International journal of medical sciences.

[8]  N. Kröger,et al.  CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  G. Visani,et al.  Deferasirox improves hematopoiesis after allogeneic hematopoietic SCT , 2014, Bone Marrow Transplantation.

[10]  Yan-rong Liu,et al.  Association of an impaired bone marrow microenvironment with secondary poor graft function after allogeneic hematopoietic stem cell transplantation. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  U. Popat,et al.  Romiplostim for delayed platelet recovery and secondary thrombocytopenia following allogeneic stem cell transplantation. , 2013, American journal of blood research.

[12]  Yu-Hong Chen,et al.  [Prevalence of EBV infection in patients with allogeneic hematopoietic stem cell transplantation]. , 2013, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi.

[13]  Xiao-jun Huang,et al.  [Cytomegalovirus-specific T cells immune reconstitution after human leukocyte antigen matched sibling donor allogeneic bone marrow plus peripheral blood hematopoietic stem cell transplantation]. , 2012, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi.

[14]  H. Einsele,et al.  Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia , 2009, Bone Marrow Transplantation.

[15]  M. Remberger,et al.  Major ABO blood group mismatch increases the risk for graft failure after unrelated donor hematopoietic stem cell transplantation. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  A. Larocca,et al.  Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. , 2006, Haematologica.

[17]  L. Adès,et al.  Granulocyte colony-stimulating factor for poor graft function after allogeneic stem cell transplantation: 3 days of G-CSF identifies long-term responders , 2005, Bone Marrow Transplantation.

[18]  J. Lee,et al.  Failure of trilineage blood cell reconstitution after initial neutrophil engraftment in patients undergoing allogeneic hematopoietic cell transplantation – frequency and outcomes , 2004, Bone Marrow Transplantation.

[19]  P. Griffiths,et al.  Definitions of cytomegalovirus infection and disease in transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  F. Frassoni,et al.  Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft‐versus‐host disease, donor type, cytomegalovirus infections and cell dose , 2001, British journal of haematology.

[21]  S. Rowley,et al.  Transplantation of ABO-incompatible bone marrow and peripheral blood stem cell components , 2000, Bone Marrow Transplantation.

[22]  J. Connors,et al.  Prolonged erythroid aplasia after major ABO-mismatched transplantation for chronic myelogenous leukemia. , 1998, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[24]  K. Sullivan,et al.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.